List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5535105/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Reduction in initiations of HIV treatment in South Africa during the COVID pandemic. BMC Health Services Research, 2022, 22, 428.	0.9	15
2	Patient Perspectives of Quality of the Same-Day Antiretroviral Therapy Initiation Process in Gauteng Province, South Africa: Qualitative Dominant Mixed-Methods Analysis of the SLATE II Trial. Patient, 2021, 14, 175-186.	1.1	3
3	Treatment outcomes and costs of a simplified antiviral treatment strategy for hepatitis C among monoinfected and HIV and/or hepatitis B virusâ€coâ€infected patients in Myanmar. Journal of Viral Hepatitis, 2021, 28, 147-158.	1.0	14
4	Adaptation of WHO's generic tuberculosis patient cost instrument for a longitudinal study in Africa. Global Health Action, 2021, 14, 1865625.	0.7	6
5	Community-based delivery of HIV treatment in Zambia: costs and outcomes. Aids, 2021, 35, 299-306.	1.0	33
6	Fast-track treatment initiation counselling in South Africa: A cost-outcomes analysis. PLoS ONE, 2021, 16, e0248551.	1.1	1
7	Economic evaluation of differentiated service delivery models for HIV treatment in Lesotho: costs to providers and patients. Journal of the International AIDS Society, 2021, 24, e25692.	1.2	20
8	The revolving door of HIV care: Revising the service delivery cascade to achieve the UNAIDS 95-95-95 goals. PLoS Medicine, 2021, 18, e1003651.	3.9	74
9	Differentiated Service Delivery Models for HIV Treatment in Malawi, South Africa, and Zambia: A Landscape Analysis. Global Health, Science and Practice, 2021, 9, 296-307.	0.6	22
10	Changing Knowledge and Attitudes Towards HIV Treatment-as-Prevention and "Undetectable = Untransmittable― A Systematic Review. AIDS and Behavior, 2021, 25, 4209-4224.	1.4	59
11	Multimonth dispensing of up to 6 months of antiretroviral therapy in Malawi and Zambia (INTERVAL): a cluster-randomised, non-blinded, non-inferiority trial. The Lancet Global Health, 2021, 9, e628-e638.	2.9	47
12	Getting resources to those who need them: the evidence we need to budget for underserved populations in subâ \in Saharan Africa. Journal of the International AIDS Society, 2021, 24, e25707.	1.2	1
13	Retention in care and viral suppression after sameâ€day ART initiation: Oneâ€year outcomes of the SLATE I and II individually randomized clinical trials in South Africa. Journal of the International AIDS Society, 2021, 24, e25825.	1.2	7
14	Economic evaluations of differentiated service delivery should include savings and ancillary benefits, not only health system costs: authors' reply. Aids, 2021, 35, 2235-2236.	1.0	0
15	Changes in HIV treatment differentiated care uptake during the COVIDâ€19 pandemic in Zambia: interrupted time series analysis. Journal of the International AIDS Society, 2021, 24, e25808.	1.2	8
16	Do differentiated service delivery models for HIV treatment in sub-Saharan Africa save money? Synthesis of evidence from field studies conducted in sub-Saharan Africa in 2017-2019. Gates Open Research, 2021, 5, 177.	2.0	5
17	Cost and Impact of Dried Blood Spot Versus Plasma Separation Card for Scale-up of Viral Load Testing in Resource-limited Settings. Clinical Infectious Diseases, 2020, 70, 1014-1020.	2.9	23
18	Eligibility for differentiated models of HIV treatment service delivery: an estimate from Malawi and Zambia. Aids, 2020, 34, 475-479.	1.0	11

#	Article	IF	CITATIONS
19	Will differentiated care for stable HIV patients reduce healthcare systems costs?. Journal of the International AIDS Society, 2020, 23, e25541.	1.2	9
20	Novel metric for evaluating pre-exposure prophylaxis programme effectiveness in real-world settings. Lancet HIV,the, 2020, 7, e294-e300.	2.1	12
21	"Patients are not the same, so we cannot treat them the same―– A qualitative content analysis of provider, patient and implementer perspectives on differentiated service delivery models for HIV treatment in South Africa. Journal of the International AIDS Society, 2020, 23, e25544.	1.2	19
22	Economic evaluation of facilityâ€based HIV selfâ€ŧesting among adult outpatients in Malawi. Journal of the International AIDS Society, 2020, 23, e25612.	1.2	13
23	Prevalence of TB symptoms, diagnosis and treatment among people living with HIV (PLHIV) not on ART presenting at outpatient clinics in South Africa and Kenya: baseline results from a clinical trial. BMJ Open, 2020, 10, e035794.	0.8	12
24	Retention in care and viral suppression in differentiated service delivery models for HIV treatment delivery in subâ€Saharan Africa: a rapid systematic review. Journal of the International AIDS Society, 2020, 23, e25640.	1.2	72
25	Emerging priorities for HIV service delivery. PLoS Medicine, 2020, 17, e1003028.	3.9	39
26	Design of a randomized controlled trial to Link Infectious and Narcology Care (LINC-II) in St. Petersburg, Russia. Addiction Science & Clinical Practice, 2020, 15, 1.	1.2	11
27	Models of service delivery for optimizing a patient's first six months on antiretroviral therapy for HIV: an applied research agenda. Gates Open Research, 2020, 4, 116.	2.0	17
28	A clinical algorithm for same-day HIV treatment initiation in settings with high TB symptom prevalence in South Africa: The SLATE II individually randomized clinical trial. PLoS Medicine, 2020, 17, e1003226.	3.9	29
29	Tailored HIV programmes and universal health coverage. Bulletin of the World Health Organization, 2020, 98, 87-94.	1.5	16
30	Adherence clubs and decentralized medication delivery to support patient retention and sustained viral suppression in care: Results from a cluster-randomized evaluation of differentiated ART delivery models in South Africa. PLoS Medicine, 2019, 16, e1002874.	3.9	80
31	Monitoring viral load for the last mile: what will it cost?. Journal of the International AIDS Society, 2019, 22, e25337.	1.2	29
32	Who is seeking antiretroviral treatment for <scp>HIV</scp> now? Characteristics of patients presenting in Kenya and South Africa in 2017â€2018. Journal of the International AIDS Society, 2019, 22, e25358.	1.2	10
33	Differentiated HIV care in South Africa: the effect of fastâ€track treatment initiation counselling on ART initiation and viral suppression as partial results of an impact evaluation on the impact of a package of services to improve HIV treatment adherence. Journal of the International AIDS Society, 2019. 22. e25409.	1.2	21
34	Optimizing viral load testing access for the last mile: Geospatial cost model for point of care instrument placement. PLoS ONE, 2019, 14, e0221586.	1.1	28
35	Simplified clinical algorithm for identifying patients eligible for same-day HIV treatment initiation (SLATE): Results from an individually randomized trial in South Africa and Kenya. PLoS Medicine, 2019, 16, e1002912.	3.9	33
36	Cost outcome analysis of decentralized care for drug-resistant tuberculosis in Johannesburg, South Africa. PLoS ONE, 2019, 14, e0217820.	1.1	11

#	Article	IF	CITATIONS
37	The impact of adverse events on health-related quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South Africa. Health and Quality of Life Outcomes, 2019, 17, 94.	1.0	20
38	Differentiated models of service delivery for antiretroviral treatment of HIV in sub-Saharan Africa: a rapid review protocol. Systematic Reviews, 2019, 8, 314.	2.5	19
39	Growth curve modelling to determine distinct BMI trajectory groups in HIV-positive adults on antiretroviral therapy in South Africa. Aids, 2019, 33, 2049-2059.	1.0	11
40	Assessing the impact of the National Department of Health's National Adherence Guidelines for Chronic Diseases in South Africa using routinely collected data: a cluster-randomised evaluation. BMJ Open, 2018, 8, e019680.	0.8	16
41	Failure to initiate HIV treatment in patients with high CD 4 counts: evidence from demographic surveillance in rural SouthÂAfrica. Tropical Medicine and International Health, 2018, 23, 206-220.	1.0	21
42	Impact of a borderless sample transport network for scaling up viral load monitoring: results of a geospatial optimization model for Zambia. Journal of the International AIDS Society, 2018, 21, e25206.	1.2	23
43	Improved simplified clinical algorithm for identifying patients eligible for immediate initiation of antiretroviral therapy for HIV (SLATE II): protocol for a randomized evaluation. Trials, 2018, 19, 548.	0.7	15
44	Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa. BMC Health Services Research, 2018, 18, 973.	0.9	26
45	Prevalence, incidence, predictors, treatment, and control of hypertension among HIV-positive adults on antiretroviral treatment in public sector treatment programs in South Africa. PLoS ONE, 2018, 13, e0204020.	1.1	53
46	Effectiveness of interventions for unstable patients on antiretroviral therapy in South Africa: results of a clusterâ€randomised evaluation. Tropical Medicine and International Health, 2018, 23, 1314-1325.	1.0	19
47	High rates of death and loss to follow-up by 12 months of rifampicin resistant TB treatment in South Africa. PLoS ONE, 2018, 13, e0205463.	1.1	8
48	Implementation of Option B and a fixed-dose combination antiretroviral regimen for prevention of mother-to-child transmission of HIV in South Africa: A model of uptake and adherence to care. PLoS ONE, 2018, 13, e0201955.	1.1	4
49	Why do people living with HIV not initiate treatment? A systematic review of qualitative evidence from low- and middle-income countries. Social Science and Medicine, 2018, 213, 72-84.	1.8	81
50	Initiating antiretroviral therapy for HIV at a patient's first clinic visit. Aids, 2017, 31, 1611-1619.	1.0	27
51	Simplified clinical algorithm for identifying patients eligible for immediate initiation of antiretroviral therapy for HIV (SLATE): protocol for a randomised evaluation. BMJ Open, 2017, 7, e016340.	0.8	15
52	Quantifying unmet need for hypertension care in South Africa through a care cascade: evidence from the SANHANES, 2011-2012. BMJ Global Health, 2017, 2, e000348.	2.0	95
53	Prevalence and unmet need for diabetes care across the care continuum in a national sample of South African adults: Evidence from the SANHANES-1, 2011-2012. PLoS ONE, 2017, 12, e0184264.	1.1	90
54	Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case. PLoS ONE, 2017, 12, e0186496.	1.1	39

ARTICLE IF CITATIONS A new cascade of HIV care for the era of "treat allâ€. PLoS Medicine, 2017, 14, e1002268. Treatment eligibility and retention in clinical HIV care: A regression discontinuity study in South 3.9 60 56 Africa. PLoS Medicine, 2017, 14, e1002463. Varying intervals of antiretroviral medication dispensing to improve outcomes for HIV patients (The) Tj ETQq1 1 0.784314 rgBT /Over Effect of eliminating CD4-count thresholds on HIV treatment initiation in South Africa: An empirical 58 1.1 20 modeling study. PLoS ONE, 2017, 12, e0178249. Treatment initiation among persons diagnosed with drug resistant tuberculosis in Johannesburg, South Africa. PLoS ONE, 2017, 12, e0181238. 1.1 Changing the South African national antiretroviral therapy guidelines: The role of cost modelling. PLoS ONE, 2017, 12, e0186557. 60 1.1 52 Interventions to improve the rate or timing of initiation of antiretroviral therapy for HIV in subâ€Saharan Africa: metaâ€analyses of effectiveness. Journal of the International AIDS Society, 2016, 19, 1.2 20888. Outcomes of treatment of drug-susceptible tuberculosis at public sector primary healthcare clinics in Johannesburg, South Africa: A retrospective cohort study. South African Medical Journal, 2016, 106, 62 0.2 11 1002. Initiating Antiretroviral Therapy for HIV at a Patient's First Clinic Visit: The RapIT Randomized 232 Controlled Trial. PLoS Medicine, 2016, 13, e1002015. Accelerating the Uptake and Timing of Antiretroviral Therapy Initiation in Sub-Saharan Africa: An 3.9 34 64 Operations Research Agenda. PLoS Medicine, 2016, 13, e1002106. Economic evaluation of a shortened standardised treatment regimen of antituberculosis drugs for 0.8 patients with multidrug-resistant tuberculosis (STREAM): study protocol. BMJ Open, 2016, 6, e014386. Early Outcomes Of Decentralized Care for Rifampicin-Resistant Tuberculosis in Johannesburg, South 66 1.1 12 Afrića: An Observational Cohort Study. PLoS ONE, 2016, 11, e0164974. Retention of Adult Patients on Antiretroviral Therapy in Low- and Middle-Income Countries. Journal 263 of Acquired Immune Deficiency Syndromes (1999), 2015, 69, 98-108. Mass HIV Treatment and Sex Disparities in Life Expectancy: Demographic Surveillance in Rural South 68 3.9 109 Africa. PLoS Medicine, 2015, 12, e1001905. Thresholds for the cost–effectiveness of interventions: alternative approaches. Bulletin of the 69 1.5 614 World Health Organization, 2015, 93, 118-124. Systematic review of retention of pediatric patients on HIV treatment in low and middle-income 70 1.0 62 countries 2008–2013. Aids, 2015, 29, 493-502. Effect of antiretroviral therapy on patients' economic well being. Aids, 2014, 28, 417-424. 71 1.0 Resource Utilization and Costs of Care prior to ART Initiation for Pediatric Patients in Zambia. AIDS 72 0.3 5

SYDNEY ROSEN

Research and Treatment, 2014, 2014, 1-5.

#	Article	IF	CITATIONS
73	Retention in care, resource utilization, and costs for adults receiving antiretroviral therapy in Zambia: a retrospective cohort study. BMC Public Health, 2014, 14, 296.	1.2	19
74	Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa. Tropical Medicine and International Health, 2013, 18, 109-116.	1.0	40
75	Cost and outcomes of paediatric antiretroviral treatment in South Africa. Aids, 2013, 27, 243-250.	1.0	23
76	Antiretroviral therapy, labor productivity, and sex. Aids, 2013, 27, 115-123.	1.0	13
77	Rates and Cost of Hospitalization Before and After Initiation of Antiretroviral Therapy in Urban and Rural Settings in South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 322-328.	0.9	35
78	ART treatment costs and retention in care in Kenya: a cohort study in three rural outpatient clinics. Journal of the International AIDS Society, 2013, 16, 18026.	1.2	39
79	Same-Day CD4 Testing to Improve Uptake of HIV Care and Treatment in South Africa: Point-of-Care Is Not Enough. AIDS Research and Treatment, 2013, 2013, 1-7.	0.3	30
80	Retention in Care and Outpatient Costs for Children Receiving Antiretroviral Therapy in Zambia: A Retrospective Cohort Analysis. PLoS ONE, 2013, 8, e67910.	1.1	20
81	HIV Treatment Produces Economic Returns Through Increased Work And Education, And Warrants Continued US Support. Health Affairs, 2012, 31, 1470-1477.	2.5	15
82	Rapid Point-of-Care CD4 Testing at Mobile HIV Testing Sites to Increase Linkage to Care. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, e13-e17.	0.9	88
83	Defining retention and attrition in preâ€antiretroviral HIV care: proposals based on experience in Africa. Tropical Medicine and International Health, 2012, 17, 1235-1244.	1.0	50
84	How to Estimate the Cost of Point-of-Care CD4 Testing in Program Settings: An Example Using the Alere Pimaâ"¢ Analyzer in South Africa. PLoS ONE, 2012, 7, e35444.	1.1	48
85	The Impact and Cost of Scaling up GeneXpert MTB/RIF in South Africa. PLoS ONE, 2012, 7, e36966.	1.1	126
86	Scaling up Xpert MTB/RIF technology: the costs of laboratory―vs. clinicâ€based rollâ€out in South Africa. Tropical Medicine and International Health, 2012, 17, 1142-1151.	1.0	54
87	The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data. Journal of the International AIDS Society, 2011, 14, 24-24.	1.2	25
88	Response to: defaulting from antiretroviral treatment programmes in subâ€Saharan Africa: a problem of definition. Tropical Medicine and International Health, 2011, 16, 392-392.	1.0	0
89	Retention in HIV Care between Testing and Treatment in Sub-Saharan Africa: A Systematic Review. PLoS Medicine, 2011, 8, e1001056.	3.9	639
90	Treatment Outcomes and Cost-Effectiveness of Shifting Management of Stable ART Patients to Nurses in South Africa: An Observational Cohort. PLoS Medicine, 2011, 8, e1001055.	3.9	106

#	Article	IF	CITATIONS
91	The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa. Aids, 2010, 24, 915-919.	1.0	83
92	Barriers to initiation of antiretroviral treatment in rural and urban areas of Zambia: a crossâ€sectional study of cost, stigma, and perceptions about ART. Journal of the International AIDS Society, 2010, 13, 8-8.	1.2	64
93	Strategies to improve patient retention on antiretroviral therapy in subâ€6aharan Africa. Tropical Medicine and International Health, 2010, 15, 70-75.	1.0	110
94	Patient retention in antiretroviral therapy programs up to three years on treatment in sub aharan Africa, 2007–2009: systematic review. Tropical Medicine and International Health, 2010, 15, 1-15.	1.0	453
95	Early loss to follow up after enrolment in preâ€ART care at a large public clinic in Johannesburg, South Africa. Tropical Medicine and International Health, 2010, 15, 43-47.	1.0	93
96	Cost of using a patient tracer to reduce loss to followâ€up and ascertain patient status in a large antiretroviral therapy program in Johannesburg, South Africa. Tropical Medicine and International Health, 2010, 15, 98-104.	1.0	41
97	Why are antiretroviral treatment patients lost to followâ€up? A qualitative study from South Africa. Tropical Medicine and International Health, 2010, 15, 48-54.	1.0	133
98	Economic Outcomes of Patients Receiving Antiretroviral Therapy for HIV/AIDS in South Africa Are Sustained through Three Years on Treatment. PLoS ONE, 2010, 5, e12731.	1.1	39
99	Improvements in physical wellbeing over the first two years on antiretroviral therapy in western Kenya. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2010, 22, 137-145.	0.6	16
100	Lost opportunities to complete CD4+ lymphocyte testing among patients who tested positive for HIV in South Africa. Bulletin of the World Health Organization, 2010, 88, 675-680.	1.5	56
101	Do the socioeconomic impacts of antiretroviral therapy vary by gender? A longitudinal study of Kenyan agricultural worker employment outcomes. BMC Public Health, 2009, 9, 240.	1.2	17
102	Economic and quality of life outcomes of antiretroviral therapy for HIV/AIDS in developing countries: a systematic literature review. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2009, 21, 1343-1356.	0.6	95
103	The outcomes and outpatient costs of different models of antiretroviral treatment delivery in South Africa. Tropical Medicine and International Health, 2008, 13, 1005-1015.	1.0	85
104	Early effects of antiretroviral therapy on work performance: preliminary results from a cohort study of Kenyan agricultural workers. Aids, 2008, 22, 421-425.	1.0	69
105	Characteristics of Patients Accessing Care and Treatment for HIV/AIDS at Public and Nongovernmental Sites in South Africa. Journal of the International Association of Providers of AIDS Care, 2008, 7, 200-207.	1.2	19
106	Differences in normal activities, job performance and symptom prevalence between patients not yet on antiretroviral therapy and patients initiating therapy in South Africa. Aids, 2008, 22, S131-S139.	1.0	38
107	Cost and Cost-Effectiveness of Switching From Stavudine to Tenofovir in First-Line Antiretroviral Regimens in South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 48, 334-344.	0.9	39
108	Patient Retention in Antiretroviral Therapy Programs in Sub-Saharan Africa: A Systematic Review. PLoS Medicine, 2007, 4, e298.	3.9	647

#	Article	IF	CITATIONS
109	The impact of AIDS on government service delivery: the case of the Zambia Wildlife Authority. Aids, 2007, 21, S53-S59.	1.0	7
110	The private sector and HIV/AIDS in Africa: taking stock of 6 years of applied research. Aids, 2007, 21, S41-S51.	1.0	63
111	Cost to patients of obtaining treatment for HIV/AIDS in South Africa. South African Medical Journal, 2007, 97, 524-9.	0.2	55
112	Rationing Antiretroviral Therapy for HIV/AIDS in Africa: Choices and Consequences. PLoS Medicine, 2005, 2, e303.	3.9	41
113	Hard choices: rationing antiretroviral therapy for HIV/AIDS in Africa. Lancet, The, 2005, 365, 354-356.	6.3	41
114	Provision of antiretroviral therapy by the private sector. Lancet, The, 2005, 365, 1925-1926.	6.3	7
115	The cost of HIV/AIDS to businesses in southern Africa. Aids, 2004, 18, 317-324.	1.0	49
116	The impact of HIV/AIDS on labour productivity in Kenya. Tropical Medicine and International Health, 2004, 9, 318-324.	1.0	126
117	Prevalence of HIV in workforces in southern Africa, 2000-2001. South African Medical Journal, 2004, 94, 125-30.	0.2	14
118	Shifting the burden: the private sector's response to the AIDS epidemic in Africa. Bulletin of the World Health Organization, 2003, 81, 131-7.	1.5	12
119	Understanding household demand for indoor air pollution control in developing countries. Social Science and Medicine, 2002, 55, 571-584.	1.8	43
120	The Economics of Air Pollution Health Risks in Russia: A Case Study of Volgograd. World Development, 1999, 27, 1803-1819.	2.6	27
121	Do differentiated service delivery models for HIV treatment in sub-Saharan Africa save money? Synthesis of evidence from field studies conducted in sub-Saharan Africa in 2017-2019. Gates Open Research, 0, 5, 177.	2.0	1